News from Eisai Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 10, 2017, 08:30 ET Combination of Lenvatinib and Pembrolizumab Results in Notable Response Rates for Patients with Advanced Renal Cell Carcinoma Based on Interim Analysis of Ongoing Phase 1b/2 Trial

Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating...


Sep 10, 2017, 06:15 ET Lenvatinib Delays Deterioration in Certain Domains of Quality of Life in Patients with Unresectable Hepatocellular Carcinoma as Compared to Sorafenib in Phase 3 REFLECT Study

Eisai Inc. announced today a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was...


Aug 31, 2017, 16:03 ET Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress

Eisai Inc. will present data from its lenvatinib (marketed as Lenvima®) clinical trial program in four difficult-to-treat cancers at the European...


Aug 28, 2017, 07:55 ET Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial

Eisai Inc. announced data from a prespecified subgroup analysis, which was published in the Journal of Clinical Oncology, showing treatment with...


Jul 26, 2017, 18:40 ET FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for...


Jul 25, 2017, 07:55 ET Eisai Submits Supplemental New Drug Application to FDA for Lenvatinib in First-Line Hepatocellular Carcinoma

Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the...


Jul 17, 2017, 07:55 ET Eisai Announces New Research at the 2017 Alzheimer's Association International Conference® (AAIC®)

Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease...


Jun 21, 2017, 08:02 ET Eisai Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study will Continue as Planned Based on Interim Safety Analysis by Independent Data Monitoring Committee (DMC)

Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as...


Jun 04, 2017, 08:30 ET Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC)

Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's...


Jun 03, 2017, 14:24 ET Further Study of Combination of Eisai's Lenvatinib and Merck's Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial

Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as...


May 31, 2017, 08:00 ET Eisai and Johns Hopkins Extend Drug Discovery Collaboration with New Licensing Agreement

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have...


May 30, 2017, 19:35 ET Eisai Enters into a New Joint Research Agreement with the Broad Institute to Develop an Antimalarial Medicine

Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that it has entered into a new joint research agreement with...


May 18, 2017, 07:55 ET Eisai Data at ASCO 2017 Annual Meeting Showcase Latest Results of Ongoing Research in Oncology

Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from...


Apr 27, 2017, 08:06 ET Meta-Analysis of Published Trials Supports the Extrapolation of Antiepileptic Drug Efficacy Data from Adult to Pediatric Patients with Primary Generalized Tonic-Clonic Seizures

Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive...


Apr 19, 2017, 08:00 ET Eisai Announces Continued Support of Initiatives for the Elimination of Lymphatic Filariasis

Eisai Inc. announced today that its parent company Tokyo, Japan-based Eisai Co., Ltd. has pledged the continuing support of its initiatives for the...


Apr 13, 2017, 08:06 ET Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual Meeting

Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a...


Mar 28, 2017, 07:55 ET Eisai to Present Clinical and Preclinical Research from Oncology Portfolio at 2017 AACR Annual Meeting

Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual...


Mar 23, 2017, 08:06 ET Eisai to Launch New Medikidz Epilepsy Comic Book at the National Walk for Epilepsy

Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the...


Mar 17, 2017, 08:00 ET Dr. Kirk Shepard appointed Senior Vice President, Global Medical Affairs of the Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice...


Jan 25, 2017, 08:00 ET Positive Topline Results of Large Phase 3 Trial Show Eisai's Lenvatinib Meets Primary Endpoint in Unresectable Hepatocellular Carcinoma

Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple...


Jan 18, 2017, 08:00 ET Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it is participating in Access Accelerated, a global...


Jan 04, 2017, 16:05 ET Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with...


Dec 19, 2016, 13:30 ET Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has...


Dec 12, 2016, 08:06 ET Eisai Presents Data on BACE Inhibitor Elenbecestat (E2609) at 9th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest...